Trial reportThe Journal of clinical psychiatry2015
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.
Trial report in The Journal of clinical psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00523718 (A Double-blind Study of Riluzole Augmentation in Serotonin Reuptake Inhibitor-refractory Obsessive-compulsive Disorder and Depression), which is not on this map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-blind Study of Riluzole Augmentation in Serotonin Reuptake Inhibitor-refractory Obsessive-compulsive Disorder and Depression
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Glutamatergic Medications for Obsessive-Compulsive and Related Disorders: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review.Neuropsychopharmacology reports · 2023Pooled it
- Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis.BMC pharmacology & toxicology · 2021Pooled it
- Trial
- Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms.The Journal of clinical psychiatry · 2020Trial
- Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study.Journal of psychopharmacology (Oxford, England) · 2020Trial
- Efficacy of Dextromethorphan Augmentation in SSRI-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial.Health science reports · 2026Article
- Hereditary Patterns and Genetic Associations in Obsessive-Compulsive Disorder (OCD): Neuropsychiatric Insights, Genetic Influences, and Treatment Perspectives.Current gene therapy · 2025Review
- Article
- Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?World journal of psychiatry · 2021Review
- Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.Psychiatry research · 2021Article
- Pharmacotherapeutic Strategies and New Targets in OCD.Current topics in behavioral neurosciences · 2021Review
- Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder.The American journal of psychiatry · 2021Review
- Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology.Frontiers in psychiatry · 2020Review
- Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder.Journal of experimental pharmacology · 2020Review
- Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives.Neuropsychiatric disease and treatment · 2020Review
- Effects of persistent sodium current blockade in respiratory circuits depend on the pharmacological mechanism of action and network dynamics.PLoS computational biology · 2019Article
- Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).Current neuropharmacology · 2019Review
- Glutamatergic augmentation strategies in obsessive-compulsive disorder.Indian journal of psychiatry · 2019Review
- The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveObsessive-compulsive disorder (OCD) affects approximately 2.5% of the population and is associated with significant morbidity. Many patients receive little benefit from the best available treatments, and even those who do respond often suffer from significant residual symptoms. Convergent evidence suggests that abnormalities in glutamate homeostasis and neurotransmission may contribute to OCD and that glutamate-modulating medications may be of benefit in patients whose symptoms are refractory to standard interventions. Small open-label trials of augmentation of serotonin reuptake inhibitor (SRI) pharmacotherapy with the glutamate modulator riluzole have suggested benefit in adults with refractory symptoms. We report a pilot randomized placebo-controlled trial of riluzole augmentation of ongoing SRI treatment in SRI-refractory patients.
methodOutpatients (n = 27) and inpatients (n = 11) with DSM-IV OCD on stable SRI pharmacotherapy were randomized between November 2006 and December 2012 to receive riluzole 50 mg or placebo twice a day and followed for 12 weeks after a 2-week placebo lead-in phase.
resultsRiluzole was well tolerated; 1 patient experienced moderate nausea, but none discontinued treatment due to side effects. While there was nominally greater Y-BOCS improvement in the riluzole group (our primary outcome) compared to placebo, it did not reach statistical significance. In the outpatient subsample, a trend suggesting benefit from riluzole augmentation for obsessions (P = .056, 2-tailed, uncorrected) was found in a secondary analysis. Among outpatients, more achieved at least a partial response (> 25% improvement) with riluzole than with placebo (P = .02 in a secondary analysis).
conclusionsRiluzole may be of benefit to a subset of patients. Larger samples would be required to detect effects of the order suggested by the nominal improvement in our outpatient subsample.
trial registrationClinicalTrials.gov identifier: NCT00523718.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.